Novartis eye drug works at less frequent dosing than rival's

ZURICH (Reuters) - Novartis eye drug RTH258 works as well as a rival product from Regeneron and at less frequent dosing in clinical trials, the Swiss drugmaker said on Tuesday, boosting its shares.